Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182Phase 3Active, not recruiting
- Sponsor
- Lumen Bioscience
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Microbiome Therapeutics, Metabolic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of LMN-201 in Clostridioides difficile infection (CDI), sponsored by Lumen Bioscience. Started Aug 2024; status: active, not recruiting.
02
Drugs
LMN-201
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05330182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330182.